Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS

Retrovirology

Iart Luca Shytaj¹  Andrea Savarino¹ 

[1] Department of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena, 299, Rome, 00161, Italy

关键词: Auranofin;    Clinical trials;    Anti-rheumatic;    Hydroxychloroquine;    Chloroquine;    HIV latency;    Immune activation;   

Others  :  1221163
DOI  :  10.1186/s12977-015-0178-0

 received in 2015-01-11, accepted in 2015-05-30,  发布年份 2015

【 摘 要 】

The restoration of the immune system prompted by antiretroviral therapy (ART) has allowed drastically reducing the mortality and morbidity of HIV infection. However, one main source of clinical concern is the persistence of immune hyperactivation in individuals under ART. Chronically enhanced levels of T-cell activation are associated with several deleterious effects which lead to faster disease progression and slower CD4 ⁺T-cell recovery during ART. In this article, we discuss the rationale, and review the results, of the use of antimalarial quinolines, such as chloroquine and its derivative hydroxychloroquine, to counteract immune activation in HIV infection. Despite the promising results of several pilot trials, the most recent clinical data indicate that antimalarial quinolines are unlikely to exert a marked beneficial effect on immune activation. Alternative approaches will likely be required to reproducibly decrease immune activation in the setting of HIV infection. If the quinoline-based strategies should nevertheless be pursued in future studies, particular care must be devoted to the dosage selection, in order to maximize the chances to obtain effective in vivo drug concentrations.

【 授权许可】

   
2015 Savarino and Shytaj

【 图 表 】

Figure1.

Figure2.

Figure3.

【 参考文献 】

• [1]Giorgi JV, Ho HN, Hirji K, Chou CC, Hultin LE, O’Rourke S et al.. CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38− CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group. J Infect Dis. 1994; 170(4):775-781.
• [2]Bofill M, Mocroft A, Lipman M, Medina E, Borthwick NJ, Sabin CA et al.. Increased numbers of primed activated CD8+ CD38+ CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS. 1996; 10(8):827-834.
• [3]Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H et al.. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003; 187(10):1534-1543.
• [4]Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narváez AB et al.. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004; 104(4):942-947.
• [5]Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K et al.. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008; 197(1):126-133.
• [6]Hatano H. Immune activation and HIV persistence: considerations for novel therapeutic interventions. Curr Opin HIV AIDS. 2013; 8(3):211-216.
• [7]Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003; 3(11):722-727.
• [8]Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol. 2001; 20(3):137-140.
• [9]de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM et al.. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014; 58(8):4875-4884.
• [10]Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC et al.. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One. 2013; 8(4):e60579.
• [11]De Clercq E. Ebola virus (EBOV) infection: therapeutic strategies. Biochem Pharmacol. 2015; 93(1):1-10.
• [12]Long J, Wright E, Molesti E, Temperton N, Barclay W (2015) Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry [v1; ref status: awaiting peer review, http://f1000r.es/510]. F1000Research 4:30
• [13]Madrid PB, Panchal R, Warren T, Shurtleff A, Endsley A, Green C et al (2015) Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis (in press)
• [14]Falzarano D, Safronetz D, Prescott J, Marzi A, Feldmann F, Feldmann H (2015) Lack of protection against Ebola virus from chloroquine in mice and hamsters. Emerg Infect Dis (in press)
• [15]Saez-Cirion A, Jacquelin B, Barré-Sinoussi F, Müller-Trutwin M. Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure? Philos Trans R Soc Lond B Biol Sci. 2014; 369(1645):20130436.
• [16]Rajasuriar R, Khoury G, Kamarulzaman A, French MA, Cameron PU, Lewin SR. Persistent immune activation in chronic HIV infection: do any interventions work? AIDS. 2013; 27(8):1199-1208.
• [17]Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG et al.. Hydroxychloroquine Trial Team: effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA. 2012; 308(4):353-361.
• [18]Routy JP, Angel J, Patel M, Kanagaratham C, Radzioch D, Kema I et al.. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Med. 2015; 16(1):48-56.
• [19]Rao UR, Naidu MU, Kumar TR, Shobha U, Askar MA, Ahmed N et al.. Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis—a double blind study. J Rheumatol. 1995; 22(7):1235-1240.
• [20]Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev. 2013; 254(1):326-342.
• [21]Paiardini M, Müller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev. 2013; 254(1):78-101.
• [22]Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013; 119:51-83.
• [23]Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med. 2011; 5(2):171-186.
• [24]Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R et al.. Positive effects of combined antiretroviral therapy on CD4+ Tcell homeostasis and function in advanced HIV disease. Science. 1997; 277(5322):112-116.
• [25]Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP et al.. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999; 179(4):859-870.
• [26]Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG et al.. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest. 2005; 115(11):3265-3275.
• [27]Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA. 1993; 90(19):8925-8928.
• [28]Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S et al.. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med. 2008; 14(10):1077-1087.
• [29]Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G et al.. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest. 2009; 119(12):3544-3555.
• [30]Sachdeva N, Asthana V, Brewer TH, Garcia D, Asthana D. Impaired restoration of plasmacytoid dendritic cells in HIV-1-infected patients with poor CD4 T cell reconstitution is associated with decrease in capacity to produce IFN-alpha but not proinflammatory cytokines. J Immunol. 2008; 181(4):2887-2897.
• [31]Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013; 119:51-83.
• [32]Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev. 2013; 26(1):2-18.
• [33]Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B et al.. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009; 15(8):893-900.
• [34]Paiardini M, Cervasi B, Reyes-Aviles E, Micci L, Ortiz AM, Chahroudi A et al.. Low levels of SIV infection in sooty mangabey central memory CD4+ T cells are associated with limited CCR5 expression. Nat Med. 2011; 17(7):830-836.
• [35]Tsai WP, Nara PL, Kung HF, Oroszlan S. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses. 1990; 6(4):481-489.
• [36]Naarding MA, Baan E, Pollakis G, Paxton WA. Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology. 2007; 4:6. BioMed Central Full Text
• [37]Forsman A, Beirnaert E, Aasa-Chapman MM, Hoorelbeke B, Hijazi K, Koh W et al.. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol. 2008; 82:12069-12081.
• [38]Savarino A, Lucia MB, ter Heine R, Rastrelli E, Rutella S, Majori G et al.. Quinoline antimalarials as investigational drugs for HIV-1/AIDS: in vitro effects on HIV-1 replication, HIV-1 response to antiretroviral drugs, and intracellular antiretroviral drug concentrations. Drug Dev Res. 2006; 67(10):806-817.
• [39]Aguirre-Cruz L, Torres KJ, Jung-Cook H, Fortuny C, Sánchez E, Soda-Mehry A et al.. Short communication: preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects. AIDS Res Hum Retroviruses. 2010; 26(3):339-342.
• [40]Klohs WD, Steinkampf RW. The effect of lysosomotropic agents and secretory inhibitors on anthracycline retention and activity in multiple drug-resistant cells. Mol Pharmacol. 1988; 34(2):180-185.
• [41]Vezmar M, Georges E. Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem Pharmacol. 2000; 59(10):1245-1252.
• [42]Boelaert JR, Sperber K. Antiretroviral treatment. Lancet. 1998; 352(9135):1224-1225.
• [43]Torres KJ, Reyes-Terán G, Sotelo J, Jung-Cook H, Aguirre-Cruz L. Influence of quinacrine and chloroquine on the in vitro 3′-azido-3′-deoxythymidine antiretroviral effect. AIDS Res Ther. 2015; 12:7.
• [44]Martinson JA, Montoya CJ, Usuga X, Ronquillo R, Landay AL, Desai SN. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob Agents Chemother. 2010; 54(2):871-881.
• [45]van Loosdregt J, Spreafico R, Rossetti M, Prakken BJ, Lotz M, Albani S (2013) Hydroxychloroquine preferentially induces apoptosis of CD45RO + effector T cells by inhibiting autophagy: a possible mechanism for therapeutic modulation of T cells. J Allergy Clin Immunol 131(5):1443–6.e1
• [46]Shytaj IL, Savarino A. A cure for AIDS: a matter of timing? Retrovirology. 2013; 10:145. BioMed Central Full Text
• [47]Chomont N, DaFonseca S, Vandergeeten C, Ancuta P, Sékaly RP. Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Curr Opin HIV AIDS. 2011; 6(1):30-36.
• [48]Chirullo B, Sgarbanti R, Limongi D, Shytaj IL, Alvarez D, Das B et al.. A candidate anti-HIV reservoir compound, auranofin, exerts a selective ‘anti-memory’ effect by exploiting the baseline oxidative status of lymphocytes. Cell Death Dis. 2013; 4:e944.
• [49]Zhan XY, Wang N, Liu G, Qin L, Xu W, Zhao S et al.. Plasmodium infection reduces the volume of the viral reservoir in SIV-infected rhesus macaques receiving antiretroviral therapy. Retrovirology. 2014; 11(1):112. BioMed Central Full Text
• [50]Li H, Hatfield G, Pauza CD (2014) Gag-mediated autophagy promotes CD4 T cell survival: a possible mechanism for HIV reservoir persistence. XX international AIDS conference, towards an HIV cure symposium; Melbourne, Australia. PE18 LB
• [51]Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC et al.. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 2012; 36(3):491-501.
• [52]Evans DT, Silvestri G. Nonhuman primate models in AIDS research. Curr Opin HIV AIDS. 2013; 8(4):255-261.
• [53]Ma JP, Xia HJ, Zhang GH, Han JB, Zhang LG, Zheng YT. Inhibitory effects of chloroquine on the activation of plasmacytoid dendritic cells in SIVmac239-infected Chinese rhesus macaques. Cell Mol Immunol. 2012; 9(5):410-416.
• [54]Vaccari M, Fenizia C, Ma ZM, Hryniewicz A, Boasso A, Doster MN et al.. Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques. AIDS Res Hum Retroviruses. 2014; 30(4):355-362.
• [55]Murray SM, Down CM, Boulware DR, Stauffer WM, Cavert WP, Schacker TW et al.. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol. 2010; 84(22):12082-12086.
• [56]Sperber K, Louie M, Kraus T, Proner J, Sapira E, Lin S et al.. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther. 1995; 17(4):622-636.
• [57]Sperber K, Chiang G, Chen H, Ross W, Chusid E, Gonchar M et al.. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther. 1997; 19(5):913-923.
• [58]Paton NI, Aboulhab J, Karim F. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1. Lancet. 2002; 359(9318):1667-1668.
• [59]Paton NI, Aboulhab J. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Med. 2005; 6(1):13-20.
• [60]Piconi S, Parisotto S, Rizzardini G, Passerini S, Terzi R, Argenteri B et al.. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood. 2011; 118(12):3263-3272.
• [61]Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J et al.. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002; 46(6):1460-1469.
• [62]Augustijns P, Geusens P, Verbeke N. Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis. Eur J Clin Pharmacol. 1992; 42(4):429-433.
• [63]Savarino A, Gennero L, Chen HC, Serrano D, Malavasi F, Boelaert JR et al.. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS. 2001; 15(17):2221-2229.
• [64]Rong L, Perelson AS. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol. 2009; 5(10):e1000533.
• [65]Sperber K, Kalb TH, Stecher VJ, Banerjee R, Mayer L. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses. 1993; 9(1):91-98.
• [66]Royle CM, Tsai MH, Tabarrini O, Massari S, Graham DR, Aquino VN et al.. Modulation of HIV-1-induced activation of plasmacytoid dendritic cells by 6-desfluoroquinolones. AIDS Res Hum Retroviruses. 2014; 30(4):345-354.
• [67]Tsang AC, Ahmadi Pirshahid S, Virgili G, Gottlieb CC, Hamilton J, Coupland SG (2015) Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test. Ophthalmology [Epub ahead of print]
• [68]Mehraj V, Jenabian MA, Vyboh K, Routy JP. Immune suppression by myeloid cells in HIV infection: new targets for immunotherapy. Open AIDS J. 2014; 8:66-78.
• [69]Suarez-Almazor ME, Spooner CH, Belseck E, Shea B (2000) Auranofin versus placebo in rheumatoid arthritis. Cochrane Database Syst Rev. (2):CD002048 (Review)
• [70]Lewis MG, DaFonseca S, Chomont N, Palamara AT, Tardugno M, Mai A et al.. Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS. 2011; 25(11):1347-1356.
• [71]Lewis D, Capell HA, McNeil CJ, Iqbal MS, Brown DH, Smith WE. Gold levels produced by treatment with auranofin and sodium aurothiomalate. Ann Rheum Dis. 1983; 42(5):566-570.
• [72]Youn HS, Lee JY, Saitoh SI, Miyake K, Hwang DH. Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4. Biochem Biophys Res Commun. 2006; 350(4):866-871.
• [73]Vint IA, Chain BM, Foreman JC. The interaction of auranofin and buthionine sulfoximine blocks activation of human peripheral T lymphocytes. Cell Immunol. 1993; 152(1):152-161.
• [74]Shytaj IL, Chirullo B, Wagner W, Ferrari MG, Sgarbanti R, Corte AD et al.. Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. Retrovirology. 2013; 10:71. BioMed Central Full Text
• [75]Gavegnano C, Detorio M, Montero C, Bosque A, Planelles V, Schinazi RF. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother. 2014; 58(4):1977-1986.